HemaSphere (Nov 2024)
Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial
- Elias K. Mai,
- Axel Nogai,
- Henk M. Lokhorst,
- Bronno van derHolt,
- Sonja Zweegman,
- Katja C. Weisel,
- Sandra Croockewit,
- Anna Jauch,
- Jens Hillengass,
- Marian Stevens‐Kroef,
- Marc S. Raab,
- Annemiek Broijl,
- Gerard M. J. Bos,
- Peter Brossart,
- Paula Ypma,
- Christine Hanoun,
- Uta Bertsch,
- Thomas Hielscher,
- Hans J. Salwender,
- Christoph Scheid,
- Hartmut Goldschmidt,
- Pieter Sonneveld
Affiliations
- Elias K. Mai
- Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany
- Axel Nogai
- Medical Clinic for Hematology Oncology and Tumor Immunology, Charité Berlin Berlin Germany
- Henk M. Lokhorst
- Department of Hematology VU University Medical Center Amsterdam The Netherlands
- Bronno van derHolt
- HOVON, Rotterdam, The Netherlands and Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands
- Sonja Zweegman
- Department of Hematology VU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands
- Katja C. Weisel
- Medical Clinic and Polyclinic II University Hospital Hamburg‐Eppendorf Hamburg Germany
- Sandra Croockewit
- Department of Hematology Radboud University Medical Center Nijmegen The Netherlands
- Anna Jauch
- Institute of Human Genetics Medical Faculty Heidelberg, University of Heidelberg Heidelberg Germany
- Jens Hillengass
- Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USA
- Marian Stevens‐Kroef
- Laboratorium Tumor Genetica Radboud University Medical Centre Nijmegen The Netherlands
- Marc S. Raab
- Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany
- Annemiek Broijl
- Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands
- Gerard M. J. Bos
- Department of Internal Medicine University Hospital Maastricht Maastricht The Netherlands
- Peter Brossart
- Internal Medicine III, Oncology, Hematology and Rheumatology University Hospital Bonn Bonn Germany
- Paula Ypma
- Department of Hematology Haga Hospital The Hague The Netherlands
- Christine Hanoun
- Department of Hematology University Hospital Essen Essen Germany
- Uta Bertsch
- Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany
- Thomas Hielscher
- Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Heidelberg Germany
- Hans J. Salwender
- Department of Hematology and Oncology Asklepios Hospital Hamburg Altona Hamburg Germany
- Christoph Scheid
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn University of Cologne Cologne Germany
- Hartmut Goldschmidt
- Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany
- Pieter Sonneveld
- Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands
- DOI
- https://doi.org/10.1002/hem3.70052
- Journal volume & issue
-
Vol. 8,
no. 11
pp. n/a – n/a
Abstract
No abstracts available.